New Antibiotic Biotech Allecra Therapeutics Gets €15 Million Series A Financing
This article was originally published in The Pink Sheet Daily
Antibiotic biotech Allecra Therapeutics announced its creation amid fresh warnings about the rising number of bacteria that resist even the most potent antibiotics, and says it aims to use the cash to fund clinical development of a pair of antibiotics against multi-drug resistant, gram-negative bacteria.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.